MMP16 Mediates a Proteolytic Switch to Promote Cell–Cell Adhesion, Collagen Alignment, and Lymphatic Invasion in Melanoma

Olga Tatti(University of Helsinki), Erika Gucciardo(University of Helsinki), Pirita Pekkonen(University of Helsinki), Tanja Holopainen(University of Helsinki), Riku Louhimo(University of Helsinki), Pauliina Repo(University of Helsinki), Pilvi Maliniemi(University of Helsinki), Jouko Lohi(University of Helsinki), Ville Rantanen(University of Helsinki), Sampsa Hautaniemi(University of Helsinki), Kari Alitalo(University of Helsinki), Annamari Ranki(University of Helsinki), Päivi M. Ojala(University of Helsinki), Jorma Keski‐Oja(University of Helsinki), Kaisa Lehti(University of Helsinki)
Cancer Research
March 26, 2015
Cited by 76Open Access
Full Text

Abstract

Lymphatic invasion and accumulation of continuous collagen bundles around tumor cells are associated with poor melanoma prognosis, but the underlying mechanisms and molecular determinants have remained unclear. We show here that a copy-number gain or overexpression of the membrane-type matrix metalloproteinase MMP16 (MT3-MMP) is associated with poor clinical outcome, collagen bundle assembly around tumor cell nests, and lymphatic invasion. In cultured WM852 melanoma cells derived from human melanoma metastasis, silencing of MMP16 resulted in cell-surface accumulation of the MMP16 substrate MMP14 (MT1-MMP) as well as L1CAM cell adhesion molecule, identified here as a novel MMP16 substrate. When limiting the activities of these trans-membrane protein substrates toward pericellular collagen degradation, cell junction disassembly, and blood endothelial transmigration, MMP16 supported nodular-type growth of adhesive collagen-surrounded melanoma cell nests, coincidentally steering cell collectives into lymphatic vessels. These results uncover a novel mechanism in melanoma pathogenesis, whereby restricted collagen infiltration and limited mesenchymal invasion are unexpectedly associated with the properties of the most aggressive tumors, revealing MMP16 as a putative indicator of adverse melanoma prognosis.


Related Papers